RT Journal Article
SR Electronic
T1 NeMoR: a New Method Based on Data-Driven for Neonatal Mortality Rate Forecasting
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.22.21255916
DO 10.1101/2021.04.22.21255916
A1 Beluzo, Carlos Eduardo
A1 Alves, Luciana Correia
A1 Arruda, Natália Martins
A1 Sepetauskas, Cátia
A1 Silva, Everton
A1 Carvalho, Tiago
YR 2021
UL http://medrxiv.org/content/early/2021/04/25/2021.04.22.21255916.abstract
AB Reduction in child mortality is one of the United Nations Sustainable Development Goals for 2030. In Brazil, despite recent reduction in child mortality in the last decades, the neonatal mortality is a persistent problem and it is associated with the quality of prenatal, childbirth care and social-environmental factors. In a proper health system, the effect of some of these factors could be minimized by the appropriate number of newborn intensive care units, number of health care units, number of neonatal incubators and even by the correct level of instruction of mothers, which can lead to a proper care along the prenatal period. With the intent of providing knowledge resources for planning public health policies focused on neonatal mortality reduction, we propose a new data-driven machine leaning method for Neonatal Mortality Rate forecasting called NeMoR, which predicts neonatal mortality rates for 4 months ahead, using NeoDeathForecast, a monthly base time series dataset composed by these factors and by neonatal mortality rates history (2006-2016), having 57,816 samples, for all 438 Brazilian administrative health regions. In order to build the model, Extra-Tree, XGBoost Regressor, Gradient Boosting Regressor and Lasso machine learning regression models were evaluated and a hyperparameters search was also performed as a fine tune step. The method has been validated using São Paulo city data, mainly because of data quality. On the better configuration the method predicted the neonatal mortality rates with a Mean Square Error lower than 0.18. Besides that, the forecast results may be useful as it provides a way for policy makers to anticipate trends on neonatal mortality rates curves, an important resource for planning public health policies.HighlightsProposition of a new data-driven approach for neonatal mortality rate forecast, which provides a way for policy-makers to anticipate trends on neonatal mortality rates curves, making a better planning of health policies focused on NMR reduction possible;a method for NMR forecasting with a MSE lower than 0.18;an extensive evaluation of different Machine Learning (ML) regression models, as well as hyperparameters search, which accounts for the last stage in NeMoR;a new time series database for NMR prediction problems;a new features projection space for NMR forecasting problems, which considerably reduces errors in NRM prediction.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was supported by Bill &; Melinda Gates Foundation (Process no: OPP1201970) and Ministry of Health of Brazil, through the National Council for Scientific and Technological Development (CNPq) (Process no: 443774/2018-8). It was also supported by NVIDIA, that donated a GPU XP Titan used by the research team.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This paper uses publicly available data that has been de-identified and was deemed exempt from approval from a human research ethics committee.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDataset and source codes used on the experiments will be made public under paper acceptance.